.png){kind=logo}
Paige Wiecinksi, PhD, DABT
Paige is a board-certified toxicologist with 10+ years of experience driving product safety, risk assessment, and regulatory strategy. She specializes in navigating scientific and regulatory uncertainty, designing toxicological testing frameworks, and translating complex data into clear, actionable insights that support agile product development and regulatory compliance.
click icon to connect with paige
More About Paige
Paige specializes in guiding product safety and regulatory strategy. She brings deep expertise in risk assessment, product safety evaluation, and toxicology leadership to support the development and commercialization of novel products in highly scrutinized markets.
Her work spans the entire product lifecycle with extensive experience developing toxicological testing strategies, designing studies, interpreting complex datasets, and delivering data-driven recommendations that support agile product development while ensuring consumer safety and regulatory compliance. She has successfully led cross-functional teams through the implementation and maturation of FDA oversight in the tobacco sector.
Paige excels in navigating ambiguity, whether working within emerging regulatory landscapes or making decisions with limited data. She leverages foundational toxicology expertise, advanced data analysis, and strategic thinking to build safety frameworks that withstand scientific scrutiny while supporting innovation. Her approach often draws from a cross section of regulated industries offering a broadened perspective on risk assessment and compliance strategy.
Her work continues to be driven by a passion for protecting consumer health, navigating ambiguity with confidence, and delivering strategic solutions in scientifically complex and tightly regulated spaces.
Education
Paige earned her Ph.D. in Molecular and Environmental Toxicology from the University of Wisconsin–Madison, specializing in nanotoxicology. She became a Diplomate of the American Board of Toxicology (DABT) in 2016.